anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention relates to the technical field of food, and in particular, relates to a five-cereal powder for patients with throat diseases to eat and a preparation method thereof, and an anti-inflammatory external-application material containing the five-cereal powder. The five-cereal powder comprises the following raw materials in parts by weight: 5 to 50 parts of corn, 5 to 50 parts of sorghum, 5 to 50 parts of buckwheat, 1 to 30 parts of glutinous millet, 1 to 30 parts of millet and 0.5 to 20 parts of probiotics. The preparation method comprises the following steps: screening the raw material components and preparing the five-cereal powder. A five-cereal liquid can be used for preparation of an anti-inflammatory external-application drug. The raw materials of the five-cereal powder have reasonable compatibility, and the five-cereal powder is a special food for people with swollen sore throat, has rich nutritional ingredients, and has the efficacies of repairing tissues, enhancing physique and improving immunity after being eaten for a long term. At the same time, the five-cereal liquid is prepared with the five-cereal powder as the raw material; and based on a theory of &#39;skin supplementing&#39;, the five-cereal liquid is externally applied on human skin and has the anti-inflammatory effect.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition inhibiting the proliferation of cancer cells, especially breast cancer, hepatic cancer, lung cancer or stomach cancer cells, thus useful for treating and diagnosing tumors.  &lt;P&gt;SOLUTION: A pharmaceutical is provided, containing a curatively effective amount of an antibody(especially, monoclonal antibody, antibody fragments, chimeric antibody, humanized antibody) that expresses effects through bonding to a polypeptide which comprises a specific amino acid sequence or an amino acid sequence where one or several amino acids are substituted, deleted or added in the above amino acid sequence and is excessively expressed in breast cancer, hepatic cancer, lung cancer or stomach cancer cells. Another version of this pharmaceutical is such that the above antibody is conjugated with a cytotoxic agent(e.g. maytansinoid, calicheamicin). A kit including an immunohistochemically analytical means that diagnoses the presence of tumor using the above antibody is also provided.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PCT No. PCT/US94/02558 Sec. 371 Date Aug. 9, 1994 Sec. 102(e) Date Aug. 9, 1994 PCT Filed Mar. 8, 1994 PCT Pub. No. WO94/20111 PCT Pub. Date Sep. 15, 1994.The present invention is directed to a method for preventing or reducing ischemia following injury, such as reperfusion injury following ischemia, cellular damage associated with ischemic episodes, such as infarctions or traumatic injuries, and thus to prevent or reduce the consequent progressive necrosis of tissue associated with such ischemia. This effect is achieved by administering DHEA or DHEA derivatives to a patient as soon as possible after the injury. The present invention is further directed to methods for preventing or reducing bacterial translocation or adult respiratory distress syndrome in a patient. Similarly, bacterial translocation and adult respiratory distress syndrome are prevented or reduced by administering DHEA or DHEA derivatives to a patient. Suitable derivatives of DHEA include, among others, 16 alpha -bromo-DHEA, androstenediol and derivatives which have side chains at the 4&#39; and/or 7&#39; positions, which do not destroy the native activity of DHEA but which are capable of inhibiting sulfotransferase to prevent the conversion of DHEA to DHEA-S.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a novel compound exhibiting excellent phosphorylation-inhibiting activities against phosphorylation of Ser 727 of STAT3, a phosphorylation-inhibiting agent comprising the novel compound, a highly safe insulin-resistance-improving agent having a molecular target and a mechanism different from conventional agents and exhibiting excellent effects on a diabetic patient, and a preventive or therapeutic agent for diabetes, and to provide an efficient screening method of at least either one of the insulin-resistance-improving agent and the preventive or therapeutic agent for diabetes.  &lt;P&gt;SOLUTION: The novel compound inhibits phosphorylation of Ser 727 of STAT3. The phosphorylation-inhibiting agent comprises the novel compound. The insulin resistance-improving agent and the preventive or therapeutic agent for diabetes are also provided. The screening method of at least either one of the insulin-resistance-improving agent and the preventive or therapeutic agent for diabetes is also provided.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an electronic medical chart system which enhances inteligibleness in a list of various kinds of information related to patients supported in the system and simply extracts necessary information corresponding to users or use situation, and a display method for its electronic medical chart recording server.  &lt;P&gt;SOLUTION: A work area 340 which has a recording area 350 and an input area 360, and a plurality of tabs 331 which switch work contents in the work area 340 are displayed on a display screen. If one of the plurality of tabs 331 is selected, information on a work content corresponding to the selected tab 331a is displayed in the work area 340. When input in the input area 360 is received, not selected tabs are switched to display of operation buttons 332, and if one of the operation buttons 332 is selected, a display content 390 corresponding to the selected operation button 332 is displayed in the recording area 350. When registration of input in the input area 360 is received, the display content of the operation button 332 is switched to display of the original tabs 331.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PURPOSE:A cardiotonic agent containing a carbostyril derivative, e.g. 6- N- methyl-N-(4-methoxybenzyl)carbamoyl -3,4-dihydrocarbostyril, and a salt thereof as active constituents with almost no increasing action on the heart rate. CONSTITUTION:A cardiotonic agent containing a carbostyril derivative expressed by formula 1 (R&lt;1&gt; is H, alkyl, alkenyl, alkynyl, etc.; R&lt;2&gt; and R&lt;3&gt; are alkyl or lower phenylalkyl or R&lt;2&gt; and R&lt;3&gt; together with N form a 5- or 6-membered saturated heterocyclic ring which may contain O or N; the carbon-carbon bond between the 3- and 4-positions of the carbostyril skeleton is a single or double bond) and a salt thereof as active constituents. The compound expressed by formulaIis obtained by reacting a carbostyril deriavative expressed by formula 2 with an amine expressed by formula 3 by the amide bond forming reaction. The compound expressed by formula 1 has improved positive inotropic action, increasing action on coronary blood stream and hypotensive action.
A single nucleotide G &gt;A polymorphism at position -126 in the promoter of the human myeloid cell leukemia-1 gene is associated with a reduced predisposition to cancer and an increased responsiveness to pro-apoptotic cancer therapeutic agents. The G&gt;;A polymorphism is in an ELK4 transcription factor binding site, which results in reduced myeloid cell leukemia-1 gene expression. Elevated levels of ELK4 and Mcl-1 protein and nucleic acids are associated with an increased predisposition to cancer and an decreased responsiveness to pro-apoptotic agents. Reduced levels of ELK4 and Mcl-1 protein and nucleic acids are associated with less of a predisposition to cancer and an increased responsiveness to pro-apoptotic cancer therapeutic agents. Methods of cancer diagnosis and/or therapy which target ELK4 and/or Mcl-1 protein and/or nucleic acids are particularly applicable to cancers such as glioma, colon cancer, lung cancer, thyroid cancer, kidney cancer and/or melanoma. Such methods and compositions may sensitize or improve responsiveness of cancer cells to pro-apoptotic agents.
The present invention discloses a cold evil-expelling Shengqisixiang bolus, which relates to a Chinese herbal medicine for curing enteritis, intestinal chilliness and other diseases. The cold evil-expelling Shengqisixiang bolus is developed for mainly solving the problem that the existing medicament for curing enteritis, intestinal chilliness and other diseases has the disadvantages of long course of treatment, slow effect, etc. The cold evil-expelling Shengqisixiang bolus is mainly prepared from 24 kinds of Chinese herbal medicines comprising astragalus root, Atractylodis Macrocephalae, cassia, fennel, clove, aucklandia root, Chiese eaglewood wood, white peony root, Diyutan, prepared rhizome of rehmannia, scutellaria root, dried tangerine peel, etc. as raw materials which are made into a bolus through processing. The cold evil-expelling Shengqisixiang bolus is used for curing enteritis and intestinal chilliness, regulating vital energy quickly, alleviating pain and reducing acid, discharging cold stasis as soon as possible and repairing goldbeater&#39;s skin. The cold evil-expelling Shengqisixiang bolus can take effect in one month.
PURPOSE: To obtain excellent dispersion stability by mixing &gt;=1 kinds of aq. dispersions of highly swelling clay ores and &gt;=1 kinds of aq. dispersions of low swelling clay ores, then drying the mixture. CONSTITUTION: The powders of the low swelling clay ores, such as calcium bentonite, of swelling power below 18ml/2g and the powders of the high swelling clay ores, such as sodium bentonite, of swelling power above 30ml/2g, both of which have a grain size of about &gt;=100μm, more preferably about 30 to 80μ are added and dispersed together with dispersants, thickeners, surfactants, etc., at need into an aq. medium, such as water, to prepare the respective aq. dispersions in which the aq. medium is about &gt;=80wt.% (hereafter %) of the dispersion mixture. Next, the aq. dispersion of the high swelling clay ores and the aq. dispersion of the low swelling clay ores are uniformly mixed in such a manner that the content of the low swelling clay ores attains about &gt;=1% and more particularly about 20 to 90% of the composite clay, by which the dispersion mixture is prepd.  The dispersion mixture is thereafter dried by blasting and is pulverized to a prescribed grain size, by which the compound clay having about &lt;=10% moisture content is obtd.
The instant invention provides a novel drug combination comprised of an HMG-CoA reductase inhibitor and a selective COX-2 inhibitor, which is useful for treating, preventing, delaying the onset of and/or reducing the risk of developing Alzheimer&#39;s disease. One object of the instant invention is to administer the above-described combination therapy to people who do not yet show clinical signs of Alzheimer&#39;s disease, but who are at risk of developing Alzheimer&#39;s disease. These individuals may already show signs of mild cognitive impairment. Toward this end, the instant invention provides methods for preventing or reducing the risk of developing Alzheimer&#39;s by administering the above-described combination therapy to said at risk persons. Such treatment may halt or reduce the rate of further cognitive decline or, in fact, reverse cognitive decline. The present invention also provides for a method of preventing cognitive impairment or dementia, reducing the risk of cognitive decline or impairment or reducing cognitive decline or impairment resulting from stroke, stroke, cerebral ischemia or de-myelinating disorders.
A system for compliant interaction between parties may include a computing device hosting a compliance and insight platform executing on the computing device. The platform may include a secure room hosted on the platform. The secure room may include a restricted environment that hosts interaction data between users based on one or more interactions rules of the secure room. The secure room may be configured to receive interaction data from a first user in the secure room, provide at least a portion of the interaction data to a second user in the secure room, and blind and restrict the first user and the second user from each other&#39;s identity. The platform may further include a moderator of the secure room. The moderator may be configured to moderate the interaction data in the first secure room.
A method and system for remotely viewing and configuring output from a medical imager is described. A medical imager having an embedded web server generates an HTML document according to medical images received from various medical modalities. Imaging information is communicated in the HTML document to allow a remote machine to manipulate the images and display the images in a manner that accurately represents their printed output by the imager. The invention thus provides accurate viewing of the medical images from a remote machine and facilitates remote configuration of the medical imager. Other advantages include the ability to easily select conversion mechanisms best suited for specific requirements of the hospital&#39;s medical modalities without traveling to the hospital and burdening medical staff. The present invention also allows for remote monitoring of operation statistics such as usage of imaging media and other supplies.
PURPOSE:To provide a novel amino acid derivative or a salt thereof having a high glutamic acid receptor-blocking activity as a glutamic acid receptor- blocking agent. CONSTITUTION:An amino acid derivative of formula I (R1 is alkyl, cycloalkyl, aryl, aralkyl, heterocyclic; R2, R3 are monoamine residue, linear polyamine residue, cyclic polyamine residue, amino acid residue; R1-R3 can have substituents; Z is CO, SO; (n) is 0, 1, 2) or a salt thereof, e.g. alpha-(1-naphthylamino)- N,N&#39;-bis(aminopropyl) malonic amide. The compound can be produced from a compound of formula II or III (X is halogen) and a compound of formula IV (R4, R5 are the protecting group of COOH) through a compound of formula V or VI. The compound has a characteristic to block the transmission of nerve by glutamic acid, and is useful as a therapeutic agent for reducing the excitation toxicity of the glutamic acid and as reagents for bio-chemical researches. The dose is usually approximately 0.1-50mg per kg of the body weight.
PROBLEM TO BE SOLVED: To obtain the subject stable emulsified preparation with improved usability, namely, having nonsticky and refreshing feel when applied, by formulating a higher alcohol, a lipophilic nonionic surfactant and a silicone oil. SOLUTION: This emulsified preparation is obtained by including (A) as the principal medicament, one or more kinds selected from urea, sodium salicylate and pyrrolidonecarboxylic acid, (B) a water-soluble polymer (pref. a carboxyvinyl polymer, its amount to be formulated being &gt;=0.15 wt.%), (C) a higher alcohol (pref. cetanol), (D) a lipophilic nonionic surfactant (pref. glycerol monofatty acid ester), and (E) a silicone oil (pref. &lt;=50 mPa/s in viscosity at normal temperatures); wherein, it is preferable that, after emulsification process, such a process as to agitate and cool a mixture component containing at least component A from a temperature of &gt;=50 deg.C is involved.
PURPOSE:To provide the dialysis pharmaceutical having excellent stability and water solubility by obtaining a mixture composed of a first granular agent contg. the electrolyte necessary for prepn. of a dialyzate without contg. bicarbonate and contg. Pharmacologically permitted org. acids. and a second granular agent contg. the bicarbonate. CONSTITUTION:This dialysis pharmaceutical is produced as the mixture composed of the first granular agent contg. at least one kind, exclusive of the bicarbonate, of the electrolytes necessary for prepn. of the dialyzate contg. at least Na&lt;+&gt;, Ca&lt;++&gt;, Cl&lt;-&gt; and HCO3&lt;-&gt; and the pharmacologically permitted solid org. acids as a PH control agent and the second granular agent contg. the bicarbonate and the remaining electrolyte used in the first granular agent. One or &gt;=2 kinds selected from a group consisting of citric acid, tartaric acid, maleic acid, oxaloacetic acid, isocitric acid and malic acid are used as the solid org. acids. One or &gt;=2 kinds selected from a group consisting of sodium bicarbonate, sodium chloride, potassium chloride, etc., are respectively used for the second granulating agent.
PURPOSE:To obtain the subject composition capable of simultaneously, and stably incorporating the identical composition with active ingredients differing in function from one another, and capable of combining an active ingredients having been difficult to combine and also presenting the synergistic effect of their functions. CONSTITUTION:This liquid three-layered composition is made up of the upper layer consisting of a liquid oily component such as liquid paraffin, silicone oil, vegetable fatty oil, animal fatty oil or fatty acid ester, the intermediate layer consisting of a liquid nonionic surfactant &gt;=500 (pref. 600-1500) in the organic value calculated from the organic conceptual projection and 0-700 (pref. 50-500) in the difference between the organic value and the inorganic value, and the lower layer consisting of a hydrotropic liquid (e.g. a polyhydric alcohol, aliphatic lower monohydric alcohol). The composition, when shaken, is readily brought to a homogeneously dispersed state which can be maintained for a desired constant time depending on the choice of the surfactant. This surfactant is e.g. a polyoxyethylene sorbitan fatty acid ester, polyoxyethylene alkyl ether.
PURPOSE:To obtain oil-soluble vitamin powder useful as formula feed for fish breeding, etc., having excellent water-dispersing and solubilizing ability comprising specific two emulsifying agents as essential components by coating and powdering an oil-soluble vitamin with melted polyethylene glycol. CONSTITUTION:A polyoxyethylene sorbitan fatty acid ester to which &lt;=10mol&lt;30mol ethylene oxide is added and a polyoxyethylene sorbitan fatty acid ester to which &lt;=30mol-&lt;=50mol ethylene oxide is added are used as essential components for emulsifying agents and coated and powdered together with an oil-soluble vitamin (e. g. vitamin A or vitamin D) and melted polyethylene glycol. The blending ratio of the components is preferably &gt;=10 pts.wt. emulsifying agents based on 90 pts.wt. oil-soluble vitamin to stably disperse the oil- soluble vitamin. The amount of the polyethylene glycol is preferably &gt;=50 pts.wt. based on 50 pts.wt. total amounts of the emulsifying agents and the oil-soluble vitamin.
FIELD: medicine, biochemistry. SUBSTANCE: invention relates to preparing glycoprotein antigen from B. pseudomallei. Method involves the use of two-day culture of virulent strain B. pseudomallei (Australian serovara) grown on cellophane film placed on solid nutrient medium surface. Culture is inactivated with acetone and an aqueous-salt extract is prepared by homogenization of 2% microbe cells suspension under mild conditions. Then homogeneity is subjected for successive fractionation by gel-filtration on carrier &#34;Toyopearl HW-60&#34;, pH 7.2, and ion-exchange chromatography on DEAE-Sephadex A-50, pH 7.7, using 0.05 M tris-HCl as a buffer solution containing sodium chloride at concentration 0-1 M. Isolated glycoprotein consists of protein and carbohydrate at ratio 1:6 that shows homogeneity at immunoelectrophoresis assay. Significant protective effect is obtained after preliminary immunization of white mice with glycoprotein infected with virulent strains of Ps. pseudomallei. Preparation can be used for melioidosis vaccine making. EFFECT: improved method of preparing. 3 tbl
A tissue engineered three-dimensional model is provided. The three-dimensional includes Ewing&#39;s sarcoma (ES) tumor cells; and an engineered human bone scaffold. The engineered human bone scaffold further includes osteoblasts that secrete substance of the human bone, and osteoclasts that absorb bone tissue during growth and healing. The engineered human bone scaffold includes the tissue engineered three dimensional model which recapitulates the osteolytic process. The engineered human bone scaffold is engineered by co-culturing of osteoblasts and osteoclasts. The osteoblast is produced by cell differentiation process from mesenchymal stem cells. The osteoclast is produced by cell differentiation from human monocytes, wherein the human monocytes are isolated from buffy coats.
&lt;P&gt;PROBLEM TO BE SOLVED: To disclose a method and device for boring a feed-out port of a useful chemical dispenser by laser.  &lt;P&gt;SOLUTION: The dispenser has a cell 32 which is formed by a wall 31 for housing a useful chemical 33 to be fed out. A laser beam is used for at least partially baking the cell 32 through the wall 31. The laser beam and the dispenser are positioned in such a manner that a specified port place on the dispenser can be irradiated with the laser beam. During a positioning period, the laser beam is de-energized. A scribing movement moves the laser beam along a channel from the port place. By the scribing movement, the wall 31 is baked by the laser beam, and the feed-out port is formed. The positioning movement and the scribing movement are controlled by a scanning system 16.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The present invention relates to sedation assessment. In order to facilitate sedation assessment in an environment of an imaging system, a sedation assessment system is provided. The sedation assessment system comprises at least one stimulus generator, a controlling device, at least one sensing device, and a sedation determination device. The controlling device is configured to generate at least one control signal including a first control signal and/or a second control signal. The at least one stimulus generator comprises a remote haptic device configured to induce, from a distance, a haptic sensation at a first impact region on a patient&#39;s skin in response to the first control signal. Additionally or alternatively, the at least one stimulus generator comprises a heating and/or cooling device attachable to a second impact region on a patient&#39;s skin and configured to heat or cool the second impact region for inducing a pain sensation in response to the second control signal. The at least one sensing device is configured to detect a patient reaction in response to the haptic sensation and/or the pain sensation. The sedation determination device is configured to determine, based on the detected patient reaction, a sedation level of the patient.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a calcium phosphate porous body having an excellent bioabsorbability by a hole suitable for advancing a living body structure formed before the porous body is buried in a living body.  &lt;P&gt;SOLUTION: This calcium phosphate porous body is provided by filling the mixture of calcium phosphate powder and water in a mold having bar-like projections 21 formed in the inner wall surface 20 thereof, hardening the mixture, and releasing the porous body from the mold. The maximum dimension of the cross section thereof is desirably be 10 to 1000 μm. The cross section of the projections is desirably be generally circular. Thus, the calcium phosphate porous body having the hole suitable for advancing the living structure formed therein can be provided.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition simply and effectively mitigating whole physical and mental symptoms related to menstruation irrespective of a period before and after menarche.  &lt;P&gt;SOLUTION: The composition comprising an extract from Zingiber officinale Roscoe and an extract from Panax ginseng C.A. Meyer known as Chinese crude drugs in addition to oil of Oenothera tetraptera Cav. and soybean isoflavone used in the West is administered to thereby effectively mitigate the whole symptoms related to the menstruation including physical symptoms such as abdominal pain, lumbago, headache and swelling of the breast and mental symptoms such as an irritable feeling. Furthermore, the period feeling the menorrhalgia is shortened.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI